NASDAQ · BRTX
Healthcare · Biotechnology
$2.64
Down-$0.06 (-2.22%)
Updated Sep 16, 2026, 12:56 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
BRTX closed at $2.64 after 20 trading sessions, up 1139.44% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $2.73 | $2.77 | $2.6202 | $2.64 | 9.66K |
| Sep 14, 2026 | $2.68 | $2.735 | $2.6578 | $2.70 | 7.2K |
| Sep 11, 2026 | $2.75 | $2.7795 | $2.63 | $2.67 | 11.65K |
| Sep 10, 2026 | $2.82 | $2.82 | $2.7013 | $2.76 | 27.77K |
| Sep 9, 2026 | $2.72 | $2.905 | $2.61 | $2.74 | 48.93K |
| Sep 8, 2026 | $2.96 | $3.23 | $2.70 | $2.8028 | 55.82K |
| Sep 4, 2026 | $2.954 | $3.00 | $2.88 | $2.96 | 40.33K |
| Sep 3, 2026 | $3.28 | $3.576 | $2.85 | $2.874 | 175.72K |
| Sep 2, 2026 | $4.06 | $4.198 | $4.014 | $4.034 | 24.46K |
| Sep 1, 2026 | $0.2014 | $0.2023 | $0.1951 | $0.1983 | 174.81K |
| Aug 31, 2026 | $0.20 | $0.205 | $0.1992 | $0.2024 | 216.17K |
| Aug 28, 2026 | $0.219 | $0.219 | $0.1965 | $0.1991 | 244.77K |
| Aug 27, 2026 | $0.225 | $0.225 | $0.197 | $0.206 | 335.61K |
| Aug 26, 2026 | $0.22 | $0.224 | $0.2134 | $0.2169 | 59.2K |
| Aug 25, 2026 | $0.229 | $0.23 | $0.214 | $0.2225 | 103.35K |
| Aug 24, 2026 | $0.2186 | $0.2297 | $0.21 | $0.2132 | 151.87K |
| Aug 21, 2026 | $0.223 | $0.223 | $0.2136 | $0.2153 | 76.19K |
| Aug 20, 2026 | $0.227 | $0.2343 | $0.22 | $0.2206 | 192.56K |
| Aug 19, 2026 | $0.2196 | $0.228 | $0.2133 | $0.2133 | 184.41K |
| Aug 18, 2026 | $0.224 | $0.2249 | $0.21 | $0.213 | 165.34K |
The latest Smart Investors Daily articles mentioning BRTX.
BRTX research
Company profile and research snapshot.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2024 | Roth MKM | Buy | — |
| Jun 12, 2024 | Roth MKM | Buy | — |
| Aug 14, 2023 | Roth MKM | Buy | — |
| Dec 7, 2022 | Roth Capital | Buy | — |
| Sep 28, 2022 | Maxim Group | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 8, 2026
Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-market session. The company's market cap stands at $11.0 million. BioRestorative Therapies (NASDAQ:BRTX) stock moved
ChartMill · Feb 25, 2026
Which stocks have an unusual volume on Wednesday?
ChartMill · Feb 25, 2026
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.
Benzinga · Feb 25, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BRTX.
